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Evidence Roadmap:
Medicare Trends in Specialty Drug Costs and Use
In 2013, AcademyHealth's Translation and Dissemination Institute launched its Listening Project, which aims to identify the most pressing health services research needs of leaders in health policy and health care delivery for the coming three to five years. The 2014 Listening Project Report identified several research and data gaps related to Medicare. In response to what we heard from the Medicare policy community, AcademyHealth has created this series of evidence roadmaps to identify existing resources related to the gaps. These roadmaps represent a selected minimal set of key resources rather than a comprehensive list of relevant research. The roadmaps are intended to help policy analysts and other research users better understand whether a perceived research gap represents an actual lack of evidence or failure of existing evidence to reach the policy arena, that is, a failure of adequate translation and dissemination. AcademyHealth undertook this roadmap with the support of the Robert Wood Johnson Foundation.
In their Listening Project interviews, members of the Medicare policy community suggested a particular need for policy-relevant research focused on the growing number of costly "specialty drugs" -often biologics* -to treat conditions that affect a relatively small number of people. Specialty drugs, including biologics, tend to be expensive and might pose a significant cost burden to Medicare. Policymakers are interested in ways to maintain access to safe and effective drugs for patients while containing cost growth. Research on the potential use of biosimilars, generic forms of biologics, and the cost impact of specialty drugs on consumers exists, but biosimilars are a new concept in U.S. policy, therefore, more research will be forthcoming with time.
